Kaufman, Jonathan L.
Mina, Roberto
Jakubowiak, Andrzej J.
Zimmerman, Todd L.
Wolf, Jeffrey J.
Lewis, Colleen
Gleason, Charise
Sharp, Cathy
Martin, Thomas
Heffner, Leonard T.
Nooka, Ajay K.
Harvey, R. Donald
Lonial, Sagar
Article History
Received: 23 June 2018
Revised: 18 September 2018
Accepted: 29 October 2018
First Online: 4 January 2019
Conflict of interest
: J.L.K. has consulted for Roche, AbbVie, Janssen, BMS, Takeda, and Karyopharm; A.J.J.: Consultant and Advisory Boards with honoraria for AbbVie, Amgen, BMS, Celgene, Karyopharm, SkylineDx, Takeda; L.T.H.: Pharmacyclics Institutional research funding and honorarium, Genentech institutional research funding; T.M. has received research support from Amgen and Sanofi-Aventis; J.W. has consulted for Takeda, Celgene, Amgen, and Novartis; R.D.H. research funding from Amgen and Novartis; A.K.N.: Advisory board: GSK, Spectrum, Celgene, Amgen, Novartis pharmaceuticals, Adaptive biotechnologies; Honorarium: BMS, Janssen pharmaceuticals; S.L. has consulted for Takeda, Celgene, Novartis, Janssen, GSK, BMS, and Merck. T.L.Z.: currently an employee of AbbVie.